PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™.
Dr. Roland Buelow, founder and CEO of OMT, commented, “Genmab is a pioneer in the use of transgenic mice to develop therapeutic antibodies. OMT’s next generation transgenic animals will help Genmab create human antibody specificities for its DuoBody®, HexaBody™ and other new technologies and thus aid in creating therapeutic antibodies with superior efficacy.”
Help employers find you! Check out all the jobs and post your resume.
